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The Nobel Prize in Physiology or Medicine for 2011 to Jules Hoffmann, Bruce Beutler, and the late
Ralph Steinman recognizes accomplishments in understanding and unifying the two strands of
immunology, the evolutionarily ancient innate immune response and modern adaptive immunity.Among the 15 Nobel prizes given for
discoveries in immunology, including the
very first, the 2011 prize can be best
compared to the 1908 prize, shared by
two giants of modern science, Paul
Ehrlich and Ilya Metchnikoff. In awarding
that prize, the Nobel committee attemp-
ted to grapple with the divide that had
already arisen in the then infant science
of immunology, using the simple award
statement, ‘‘in recognition of their work
on immunity.’’
In fact, Ehrlich (Ehrlich, 1900) and
Metchnikoff (Metchnikoff, 1891) were the
champions of two divergent views of how
the body protects itself against foreign
invaders. The one concentrated on the
exquisitely specific adaptive immune re-
sponse that exhibited the features of
learning and recall and was the basis
of the remarkably successful procedure
of vaccination, the only medical interven-
tion that has eradicated diseases (two so
far, smallpox in humans and rinderpest
in cattle). By contrast, the adherents of
innate immunity emphasized the near
universal capacity of multicellular life
forms, including plants, to protect them-
selves against foreign invaders with ex-
tremely effective tools to eliminate or
control the invader utilizing the inflamma-
tory system.
We return to this divide in 2011, but not
in the stark terms that separated Ehrlich
and Metchnikoff. For the work of the
new Nobel Laureates—Jules Hoffmann
and Bruce Beutler, ‘‘for their discoveries
concerning the activation of innate immu-
nity’’ and the late Ralph Steinman, ‘‘for
his discovery of the dendritic cell and its
role in adaptive immunity’’ —to a very
large degree represents the merging of
the two strands and the recognition of
the fundamental unity of immune respon-1212 Cell 147, December 9, 2011 ª2011 Elsesiveness. The celebration of immunolo-
gists everywhere in response to this
well-deserved prize is tempered with
sadness, with Ralph Steinman having
died on the Friday preceding the Monday
announcement of the award.
Exploring Immunology’s ‘‘Dirty
Little Secret’’
The narrative underlying the award to
Hoffmann and Beutler, representing
innate immunity, and Steinman, very
much on the interface between innate
and adaptive responses, begins with two
independent themes. Although Stein-
man’s key discovery was made earlier, I
start with a description of the reawaken-
ing of the interest of immunologists in
innate immunity. It would be presump-
tuous to imply that the study of the innate
immune system had ceased in the years
after Metchnikoff’s work. But there can
be little doubt that, following the proposal
by David Talmage (Talmage, 1957) and
by Macfarlane Burnet (Burnet, 1957) of
the clonal selection theory of immunity,
the attention of the majority of immunolo-
gists was riveted on the adaptive system,
and most of the other Nobel prizes in
immunology (although not all) were for
advances in understanding adaptive
immunity.
Yet despite this great attention, all was
not well in the understanding of how
adaptive immune responses were initi-
ated. A great challenge was to determine
why the simple introduction of an anti-
genic protein led to a very weak response
or tolerance unless an adjuvant was
co-injected to enhance the response.
Perhaps the most famous of these was
introduced by my predecessor twice
removed as chief of the NIAID Laboratory
of Immunology, Jules Freund, known forvier Inc.the eponymous complete Freund’s adju-
vant, consisting of killed Mycobacteria
tuberculosis organisms in a water-in-oil
emulsion.
Although this need to use adjuvants to
obtain a robust immune response to
protein antigens was widely appreciated,
it was papered over as immunologists’
‘‘dirty little secret.’’ In a remarkably
prescient and influential lecture at the
opening of the 1989 Cold Spring Harbor
Symposium on Quantitative Biology
(Janeway, 1989), Charles Janeway moti-
vated immunologists everywhere to think
about this problem. Janeway argued
that the immune system required not
only an antigen/receptor interaction to
initiate a response, but a parallel recog-
nition of structures that pathogens ex-
pressed (pathogen-associated molecular
patterns [PAMPs]), which would be rec-
ognized by receptors broadly expressed
by cells of the immune and inflammatory
systems (pattern recognition receptors
[PRRs]). He posited that these interac-
tions stimulated cellular events that were
essential for the activation, expansion,
and differentiation of T and B lympho-
cytes that would eventually result in elim-
ination or control of the pathogen.
Janeway’s proposal of a microbial
sensor eliciting an innate immune re-
sponse that was subsequently interpreted
by lymphocytes, the key cells of the adap-
tive immune system, as ‘‘permission’’ to
mount a response when they recognized
an antigenic substance was enormously
influential. Although there was ‘‘no flesh
on the bones,’’ as I will recount later, the
cell that interpreted the innate response
to the adaptive system, the dendritic
cell, had already been discovered by
Ralph Steinman. The key step, the finding
of molecular entities that represented the
PRRs and the PAMPs, was what truly
galvanized the immunological community
and led to a revolution in how we under-
stand host-pathogen interactions.
In 1996, Jules Hoffmann, with his
colleagues Lemaitre, Nicolas, Michaut,
and Reichhart, working at the Institut de
Biologie Mole´culaire et Cellulaire in Stras-
bourg, reported that, in Drosophila, an
intact gene cassette consisting of spa¨t-
zle/Toll/cactus/dorsal was essential if
the fly was to mount a potent antifungal
response (Lemaitre et al., 1996). It had
already been shown that fly resistance
to certain bacterial infections was con-
trolled by the gene designated immune
deficiency (imd), but it was clear that
many other infections were not controlled
by the action of imd alone. Hoffmann and
his colleagues became interested in the
system that activated the morphogen
dorsal because its signaling pathway,
initiated by Toll, showed a striking
similarity to components of a key activator
of vertebrate immune/inflammatory re-
sponses, the interleukin 1 (IL-1)/NF-kB
signaling pathway. The cytosolic portion
of Toll exhibits homology to the compa-
rable region of the IL-1 receptor, and
cactus is homologous to a key regulator
of NF-kB activation, I-kB, and likewise
dorsal to NF-kB. Hoffmann and his
colleagues showed that the spa¨tzle/Toll/
cactus/dorsal signaling pathway con-
trols the production of the antifungal
peptide drosomycin and that flies with
mutations in this pathway have a dramatic
reduction of survival following fungal
infection.
This finding was enormously exciting
not only for the insight that it gave into
how flies (and presumably other inverte-
brates) protected themselves against
key pathogens, but also because its
homology to components of the NF-kB
system implied that it was likely that
humans and other vertebrates might use
a related system. However, there was
one important point that led to some
uncertainty. The activator spa¨tzle, like
human IL-1, was an endogenous extra-
cellular protein, so if this pathway was
indeed Janeway’s PRR-signaling path-
way, how exactly did it sense the path-
ogen, and how would pathogen sensing
occur in vertebrates?
Before describing Beutler’s contribu-
tion, which gave us insight into the ligandsthat activated the system in humans,
there is an important intermediate finding.
Charles Janeway and his then postdoc-
toral fellow Ruslan Medzhitov, working at
Yale University, immediately recognized
that the finding by Hoffmann in flies
provided a powerful tool that might aid
in determining the nature of microbial
sensors in humans. Medzhitov and Jane-
way scanned the expressed sequence
tag database and found a transcript that
encoded a homolog of Drosophila Toll.
They wished to determine whether this
human Toll homolog initiated activation
of NF-kB, as Drosophila Toll did, and led
to the release of key proinflammatory
cytokines. Because Medzhitov and Jane-
way did not know the ligand for their
‘‘Toll-like receptor’’ (TLR), they prepared
a molecular chimera in which the extra-
cellular domain of the T cell differentiation
marker CD4 was linked to the cytosolic
domain of the TLR that they had identi-
fied. They expressed this chimera in a
human monocyte cell line and showed
that, when crosslinked with an anti-CD4
antibody, NF-kB was activated and a
series of proinflammatory cytokines
were produced, including IL-1, IL-6, and
IL-8. This work, published in 1997 (Medz-
hitov et al., 1997), established that
humans had at least one Toll homolog
(this proved to be TLR4) and that its
signaling properties resembled those of
Drosophila Toll and of human IL-1. This
still left unknown what TLRs recognized
and thus whether the TLRs were the
microbial sensors/PRRs that Janeway
had postulated. Tragically, Janeway died
in 2003. By way of disclosure, I had the
good fortune to be his postdoctoral
mentor.
The illumination of TLR recognition
specificity came from the efforts of
Bruce Beutler. Beutler had been a post-
doctoral fellow at the Rockefeller Univer-
sity working with Anthony Cerami, where
they codiscovered the proinflammatory
cytokine TNFa (Beutler et al., 1985). He
then joined the faculty of the University
of Texas Southwestern Medical Center
in Dallas, where he set himself the task
of determining the genetic defect that
rendered some mice unresponsive to
lipopolysaccharide (LPS), a bacterial en-
dotoxin. He took advantage of the exis-
tence of two sets of closely related
strains of mice, C3H/HeJ/C3H/HeN andCell 147, DC57BL/10ScCr/ C57BL/10ScSn, one of
which could respond to LPS and one
that failed to respond. To type these
mice, he made use of the capacity of
macrophages from wild-type mice to pro-
duce TNFa upon stimulation with LPS
and the failure of macrophages from
mutant mice to do so. Using a positional
cloning effort over a period of several
years, he reported in 1998 (Poltorak
et al., 1998) that the gene that was mutant
in the LPS unresponsive mice was Tlr4,
which coded for the very TLR that Medz-
hitov and Janeway had shown could acti-
vate NF-kB and cause proinflammatory
cytokine production when crosslinked.
This indicated that LPS was a direct or
indirect ligand for TLR4 and showed
that precisely the type of molecule that
would fit into Janeway’s postulated set
of PAMPs could activate production of
potent mediators of inflammation.
Of course, as is true of all seminal
discoveries, what I have described is
merely the thin edge of the wedge. The
study of the TLRs as microbial sensors
has truly burgeoned, enlisting a legion of
extremely gifted investigators who have
identified ligands for each of the TLRs.
Of these, Shizuo Akira of Osaka University
is the generally acknowledged leader,
combining gene knockout technology
and elegant biochemistry to determine
which of the microbial products activate
which TLRs. The ligands include double-
stranded RNA, single-stranded RNA,
CpG oligodeoxynucleotides, bacterial
flagellin, lipopeptides, and zymosan, a
list that is precisely one that Janeway
would have constructed as among his
PAMPs. These scientists have worked
out TLR subcellular localization (some
are in endocytic vesicles, others on the
cell surface) and have determined in detail
the signaling mechanisms and the prod-
ucts of these signaling pathways. Indeed,
shortly after Beutler’s publication that
TLR4 controlled LPS responses, Akira
and his colleagues reported that deleting
Myd88, a key signaling intermediate in
the IL-1 pathway, blocked much of the
action of LPS (Kawai et al., 1999).
Equally important has been the rec-
ognition that the TLRs are but one system
of microbial sensors. Other PRRs exist—
some that have been long-known and
others, particularly those found in the
cytosol, that have been recently identified.ecember 9, 2011 ª2011 Elsevier Inc. 1213
In some cases, a recognition element is
linked through an intermediate to an
effector, often by assembly into a molec-
ular complex, an inflammasome. Often,
the key effector event is the activation
of caspase 1 so that it can cleave its
targets, one of the most important being
pro-IL-1b, giving rise to biologically active
IL-1b.
The Unification of Innate and
Adaptive Immunity
The adaptive system consists of two
broad sets of antigen-responsive cells,
the B and T lymphocytes. B lymphocytes
are the precursors of antibody-producing
cells, and they use antibody in a mem-
brane protein from as their antigen-
binding receptors. Antibodies are capable
of recognizing three-dimensional struc-
tures and thus can interact with and
lead to the neutralization of pathogens in
extracellular fluid. B cell receptors recog-
nize the same structures, and though it
now appears that this recognition often
occurs on cell surfaces, soluble mole-
cules can certainly bind to B cell receptors
and, when in a multivalent conformation,
can elicit stimulatory signals in the B cell.
By contrast, the T cell antigen recogni-
tion system is not adapted to the rec-
ognition of three-dimensional structures
on the surface of pathogens. Rather,
T cell receptors recognize a complex
consisting of an antigen-derived peptide
bound into a specialized groove in class
I and class II major histocompatibility
complex (MHC) molecules. As such,
T cell recognition of antigen occurs on
the surface of cells expressing these
peptide/MHC complexes, often referred
to as antigen-presenting cells (APCs). In
the late 1960s and early 1970s, when the
requirement for APCs was first appreci-
ated, it was generally believed that mac-
rophages and possibly B cells were the
major APCs. In 1973, Ralph Steinman
and his mentor at the Rockefeller Univer-
sity, Zanvil Cohn (who died in 1993), iden-
tified a rare cell in spleen and lymph nodes
of mice (Steinman and Cohn, 1973).
These cells had a stellate morphology;
Steinman and Cohn designated them
dendritic cells. In 1974, they published
evidence that these cells had potent
immunostimulatory activity (Steinman
and Cohn, 1974). This report was initially
received with some skepticism, based1214 Cell 147, December 9, 2011 ª2011 Elseon the widely held view that the major
APCs were the far more numerous mac-
rophages and on the uncertainty that
many immunologists had about the
assay that Steinman and Cohn used to
establish the function of their dendritic
cells.
One major function mediated by T cells
is the response to the major histocom-
patibility antigens expressed by animals
of distinct MHC type. The in vitro assay
that was used to measure this was the
‘‘mixed lymphocyte response’’ (MLR) in
which T cells from mice of one MHC
type would proliferate vigorously when
stimulated by APCs from mice of another
MHC type. Given that the nature of the
actual entity recognized in the MLR was
not clear and no T cell priming was
required to obtain a vigorous response,
many immunologists who studied T cell
responses to conventional antigens and
measured in vitro T cell proliferation
when primed cells were challenged with
antigen were uncertain as to the proper
interpretation of the MLR data. However,
this uncertainty was resolved in a series
of experiments, beginning with a key
study done by Michel Nussenzweig (then
a Ph.D. student) with Steinman and
Cohn (Nussenzweig et al., 1980), in which
it was shown that dendritic cells were
the key APCs for the development of
antigen-specific cytotoxic T cells. This
series of studies demonstrated the critical
role of dendritic cells in nearly all aspects
of T cell activation and established that
their potency as APCs far exceeded that
of other cell types that expressed MHC
molecules, most particularly of macro-
phages and B cells. Indeed, modern
techniques that led to the deletion of
dendritic cells result in a profound inability
to mount adaptive immune responses.
Dendritic cells consist of many
subtypes, but the principles underlying
their function, largely established by
Steinman and his colleagues, are quite
similar. They are found in nearly every
organ and initially exist in a state in which
they are adapted to the capture of antigen
and to the receipt of activating signals.
An illustrative example is a population of
skin cells known as epidermal Langer-
hans cells. These skin cells express cell
surface molecules that aid in the capture
of antigen. They include Fc receptors,
which are effective in binding of antigen-vier Inc.antibody complexes, receptors for com-
plement, mannose receptors and lectins,
and receptors for dying cells, among
many others. They also express TLRs.
Thus, as sentinels in the tissues, Langer-
hans cells (and other tissue dendritic
cells) can capture antigen from patho-
genic microbes or from other cells in-
fected by those organisms. They possess
the microbial sensors that determine how
they should behave. If appropriately
stimulated (for example, by LPS acting
on TLR4), they change their phenotype
from cells specialized for antigen capture
to cells adapted for antigen presentation,
and they migrate from the tissue into the
draining lymph node. These stimulated
dendritic cells acquire enhanced capacity
to process and present antigen, including
the striking upregulation of class II MHC
molecules; they increase their expression
of potent costimulatory molecules such
as CD80 and CD86 as well as Notch
ligands that allow them to efficiently acti-
vate those CD4 or CD8 T cells that have
recognized antigen on their surface, and
they secrete cytokines important in the
differentiation of the activated T cells,
such as IL-6, IL-12, and IL-23. Indeed,
the pattern of cytokines that the dendritic
cells produce and their efficiency in
processing antigen to a large extent
determine the phenotype that the differ-
entiating T cells will adopt. Among CD4
T cells, this would be whether they de-
velop into Th1, Th2, Th17, or induced T
regulatory cells and thus regulate immune
responses adapted to control distinct
types of infections.
Steinman and Nussenzweig also pio-
neered the idea that a population of den-
dritic cells resident in lymphoid tissues
continuously capture self-antigens and
present these antigens to circulating
T cells that are specific for them in inter-
actions that, rather than activating the
cells, lead either to their elimination or to
their development into regulatory T cells
(Tregs), effectively enforcing peripheral
immunologic tolerance (Hawiger et al.,
2001).
One of Steinman’s visions was the
use of dendritic cells to develop a new
generation of vaccines in which antigens
were loaded into dendritic cells in vitro
and reinjected or vaccine antigens would
be targeted to them and efficiently
loaded in vivo. Major efforts at developing
dendritic cell-based vaccines are under-
way (Steinman, 2008). Indeed, during his
long bout with pancreatic cancer, Stein-
man was treated with a dendritic cell
vaccine prepared with antigens derived
from his tumor cells.
The 2011 Nobel Prize in Physiology or
Medicine honors three remarkable scien-
tists and recognizes the effort to unite
the disparate strands of immunology by
the merging of the innate and adaptive
systems into a coherent system.
Interestingly, two other prizes have
been awarded for innate immunity almost
simultaneously with the Nobel Prize. The
Shaw Prize, sometimes described as
the ‘‘Asian Nobel,’’ went to Hoffmann,
Medzhitov, andBeutler, and the Canadian
Gairdner International Award went toHoffmann and Akira. Thus, all of the prin-
cipal living players in this story received
recognition.
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